Commerzbank employees voice UniCredit deal concerns in Brussels
Italy's UniCredit last week doubled its shareholding in the German lender as it pushes for a tie-up between the banks, despite resistance from Commerzbank management, employees and the German government.
"We made clear that a takeover would not be progress towards a European banking union," Commerzbank supervisory board member Nina Olderdissen said in a post on LinkedIn about the Brussels meetings.
"What may seem like a step towards European integration actually harbors considerable risks for employees, customers and investors on both sides - without any discernible added value," she wrote.
UniCredit first emerged as big investor in Commerzbank in September. Its CEO, Andrea Orcel, has said a deal "would create a new national banking champion for Germany", aiding "the revitalisation of the German economy".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Lleida.net increases its Q2 2025 EBITDA by 33 percent
Madrid, July 28.- Technology services company (BME: LLN) (EPA: ALLN) (OTCQX: LLEIF) reported EBITDA of €971,000 in the second quarter of 2025, up 33 percent from the same period last year, according to preliminary results presented to the market today. This growth was driven by a significant increase in revenue from certified electronic notification and contracting services, which grew by double digits. During the period, the company's pre-tax profit reached €296,000, up 97 percent from the second quarter of 2024. Overall, the company reported a turnover of 4.84 million euros in the second quarter of 2025, in line with its turnover in the same quarter last year. As of June 30, 2025, the company recorded a cumulative turnover of $10.13 million, representing a six percent increase over the same period last year. Similarly, it recorded a cumulative EBITDA of €2.195 million, showing a 57% increase over the previous year. However, its cumulative pre-tax profit for 2025 has already grown to €937,000, two and a half times higher than that recorded in the summer of 2024. "For another quarter, the company has grown by double digits, with figures that confirm that our current policy, focused on optimizing commercial efforts and strengthening the technology area, is yielding good results," explained Sisco Sapena, CEO and founder of the company. In terms of debt, the company has net financial debt of €6.29 million, down from €7.41 million at the end of 2024. The business line that has grown the most this quarter is certified electronic notification, which increased by 22 percent to €643,000. Similarly, the certified electronic contracting line increased by 15 percent to €904,000. The ICX Wholesale line decreased by eight percent, while the Other SaaS line decreased by 39 percent. The company's SMS solutions also increased by 14 percent to €1.14 million compared to the same quarter last year. Founded in 1995, is one of Europe's leading providers of certification, notification, and registered electronic signature services. The company holds more than 300 patents in over 60 countries, covering the fields of certified electronic notification, contracting, and signatures. Its shares have been traded on BME Growth (Madrid), Euronext Paris, OTCQX in New York, as well as Stuttgart and Frankfurt. Last June, the company became the first BME Growth-listed company to achieve full gender parity on its Board of Directors, following the appointment of four new independent female directors. SAFE HARBOR STATEMENTThis press release contains statements regarding the future of the company and its innovations. Statements regarding the future may be accompanied by words such as "anticipate," "believe," "estimate," "wait," "anticipate," "pretend," "power," "plan," "potential," the use of future time and other terms of similar meaning. No undue reliance should be placed on these claims. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of the company's commercial success, ability to protect our intellectual property rights, and other risks. These statements are based on current beliefs and forecasts and refer only to the date of this press release. The company assumes no obligation to publicly update its forward-looking statements, regardless of whether new information, future events or any other circumstances arise. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg® currently under review for potential approval by the EMA and MaaT033 currently in Phase 2b clinical evaluation Funding is part of the European Investment Bank (EIB)'s strategy to support biotech companies with cutting-edge expertise in therapeutic areas such as hemato-oncology Structured Debt financing from the EIB is another stepping stone in MaaT Pharma's multi-sourcing financing strategy LYON, France, July 28, 2025--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: "We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg®(MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy." Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. View source version on Contacts EIB Andrea Morawski, mobile: +352 691 284 349Website: – Press Office: press@ MaaT Pharma – Investor Relations Guilhaume DEBROAS, of Investor Relations+33 6 16 48 92 50invest@ MaaT Pharma – Media Relations Pauline RICHAUDSenior PR & Corporate Communications Manager+33 6 14 06 45 92media@ Catalytic Agency – U.S. Media Relations Heather SheaMedia relations for MaaT Pharma+1
Yahoo
20 minutes ago
- Yahoo
Atalanta eye move for Everton striker Beto
Everton striker Beto is a target for Serie A side Atalanta as they look to bolster their attack ahead of next season, per La Gazzetta dello Sport (via Tuttomercatoweb). The 2023/24 Europa League champions are in the market for a striker after losing Mateo Retegui to Saudi Pro League side Al-Qadsiah. Ademola Lookman could also leave this summer for Atletico Madrid or Inter Milan. Atalanta have turned to the Everton centre-forward, who knows Serie A well from his time with Udinese, where he scored 22 times in 65 appearances. The Toffees picked Beto up from the Italian side. Everton already spent £27 million to sign Thierno Barry from Villarreal and might consider letting Beto leave. The manager might not welcome the idea after seeing Armando Broja and Dominic Calvert-Lewin leave. The Toffees are light in front, and sanctioning Beto's exit might not be wise. Beto bagged eight goals and two assists in 30 Premier League appearances last term. Everton should hold on to Beto unless Atalanta can cough up serious money (View). He is far from the most prolific striker. However, he remains a wise squad option, especially under David Moyes. His size, work rate, and willingness to press make him an ideal back-up to Barry, who will need time to adapt to the Premier League. With Calvert-Lewin and Broja gone, Everton cannot afford to weaken their frontline further. Beto knows his role and fits Moyes' physical, direct system. His hold-up play, aerial ability, and link-up strengths remain underrated. Atalanta might be tempted by his Serie A experience, but unless they are offering enough to fund a clear upgrade, Everton should resist. Moyes needs depth and reliability, not another hole to patch. Beto, who earns £50,000 per week, is the right man to keep around, unless the money is too good to refuse.
